CCR3 and Choroidal Neovascularization
Authors:
Open Access
- 15 February 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (2) , e17106
Abstract
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in industrialized countries. The “wet” AMD, characterized by the development of choroidal neovacularization (CNV), could result in rapid and severe loss of central vision. The critical role of vascular endothelial growth factor A (VEGF-A) in CNV development has been established and VEGF-A neutralization has become the standard care for wet AMD. Recently, CCR3 was reported to play an important role in CNV development and that CCR3 targeting was reported to be superior to VEGF-A targeting in CNV suppression. We investigated the role of CCR3 in CNV development using the Matrigel induced CNV and found that in both rats and mice, CNV was well-developed in the control eyes as well as in eyes treated with CCR3 antagonist SB328437 or CCR3 neutralizing antibodies. No statistically significant difference in CNV areas was found between the control and SB328437 or CCR3-ab treated eyes. Immunostaining showed no specific expression of CCR3 in or near CNV. In contrast, both VEGF-A neutralizing antibodies and rapamycin significantly suppressed CNV. These results indicate that CCR3 plays no significant role in CNV development and question the therapeutic approach of CCR3 targeting to suppress CNV. On the other hand, our data support the therapeutic strategies of VEGF-A and mTOR (mammalian target of rapamycin) targeting for CNV.Keywords
This publication has 38 references indexed in Scilit:
- A Subretinal Matrigel Rat Choroidal Neovascularization (CNV) Model and Inhibition of CNV and Associated Inflammation and Fibrosis by VEGF TrapInvestigative Ophthalmology & Visual Science, 2010
- The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degenerationProgress in Retinal and Eye Research, 2008
- Vascular endothelial growth factor in eye diseaseProgress in Retinal and Eye Research, 2008
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Systemic rapamycin inhibits retinal and choroidal neovascularization in mice.2004
- Asthma: Mechanisms of Disease Persistence and ProgressionAnnual Review of Immunology, 2004
- Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factorNature Medicine, 2002
- Complete amino acid sequence of the FK506 and rapamycin binding protein, FKBP, isolated from calf thymusThe Protein Journal, 1991
- Inhibition of the immune response by rapamycin, a new antifungal antibioticCanadian Journal of Physiology and Pharmacology, 1977
- Vascular reactions to histamine, histamine‐liberator and leukotaxine in the skin of guinea‐pigsThe Journal of Physiology, 1952